Abstract:Visual deficits are commonly seen in patients with Alzheimer’s disease (AD), but postmortem histology has not found substantial damage in visual cortex regions, leading to the hypothesis that the visual pathway, from eye to the brain, may be damaged in AD. Diffusion tensor imaging (DTI) has been used to characterize white matter abnormalities. However, there is a lack of data examining the optic nerves and tracts in patients with AD. In this study, we used DTI to analyze the visual pathway in healthy controls,… Show more
“…In patients with AD, diffuse tensor imaging shows increase in total diffusivity, radial diffusivity and decreased fractional isotropy in the optic nerves (Nishioka et al 2015). This technique is sensitive and specific and has been used to demonstrate beta-amyloid plaques ex vivo in mouse and human retina and in vitro screening of chemical compounds for amyloidogenesis.…”
Section: Fluorescent Ligand Eye Scanning System (Fles)mentioning
Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of senile dementia. It impairs the quality of life of a person and their family, posing a serious economic and social threat in developed countries. The fact that the diagnosis can only be definitively made post‐mortem, or when the disease is fairly advanced, presents a serious problem if novel therapeutic interventions are to be devised and used early in the course of the disease. There is therefore a pressing need for more sensitive and specific diagnostic tests with which we can detect AD in the preclinical stage. The tau proteins and beta‐amyloid proteins start to accumulate 20 years before the symptoms begin to manifest. Detecting them in the preclinical stage would be a potential breakthrough in the management of AD. A high degree of clinical suspicion is needed to correlate problems in cognition with the changes in the eye, particularly the retina, pupil and ocular movements, so that the disease can be detected early and managed in the prodromal phase. In this systematic review, we ask the question whether the retina can be used to make a specific and early diagnosis of AD.
“…In patients with AD, diffuse tensor imaging shows increase in total diffusivity, radial diffusivity and decreased fractional isotropy in the optic nerves (Nishioka et al 2015). This technique is sensitive and specific and has been used to demonstrate beta-amyloid plaques ex vivo in mouse and human retina and in vitro screening of chemical compounds for amyloidogenesis.…”
Section: Fluorescent Ligand Eye Scanning System (Fles)mentioning
Alzheimer's disease (AD) is a neurodegenerative disease and the most common cause of senile dementia. It impairs the quality of life of a person and their family, posing a serious economic and social threat in developed countries. The fact that the diagnosis can only be definitively made post‐mortem, or when the disease is fairly advanced, presents a serious problem if novel therapeutic interventions are to be devised and used early in the course of the disease. There is therefore a pressing need for more sensitive and specific diagnostic tests with which we can detect AD in the preclinical stage. The tau proteins and beta‐amyloid proteins start to accumulate 20 years before the symptoms begin to manifest. Detecting them in the preclinical stage would be a potential breakthrough in the management of AD. A high degree of clinical suspicion is needed to correlate problems in cognition with the changes in the eye, particularly the retina, pupil and ocular movements, so that the disease can be detected early and managed in the prodromal phase. In this systematic review, we ask the question whether the retina can be used to make a specific and early diagnosis of AD.
“…On the other side, Alichniewicz et al (17) found decreased activation in frontal eyes fields, and Jacobs et al (18) found increased activation in the visual pathways of MCI and early AD patients. By using diffusion tension imaging, Nishioka et al (19) demonstrated that the visual pathway from the eyes to the brain is affected both in the MCI and, to a greater extend, in the AD; pathological changes were found mainly in the optic nerves. In a heterogenous series of patients with tau pathology, Rahimi et al (20) found tau deposition both in the optic nerve and in the lateral geniculate nucleus.…”
Context: Visual disturbances are frequent in Alzheimer's disease (AD) and sometimes AD begins with visual disturbances, therefore many researchers have examined the eyes in order to confirm the diagnosis, to monitor the development of the disease or the response to drugs. Evidence Acquisition: Medline literature until March 2018. Results: Several indications suggest an early involvement of the visual system in AD, yet this evidence remains inconclusive. The reason for this uncertainty is two folds: The poor quality of the studies and the fact that some alterations are not unique to the AD, since they also occur in others degenerative CNS diseases. Conclusions: The eye can be a perfect place for early diagnosis of AD and to evaluate the effectiveness of therapies more studies are needed.
“…doi:10.1017/S1041610219001418 extracellular space enlargement in GM (Elman et al, 2017;Neil et al, 2002). Many previous DTI studies have revealed altered FA and MD even in normal aging (Abe et al, 2008;Benedetti et al, 2006;Garcia-Lazaro et al, 2016), age-related neurodegenerative diseases, such as mild cognitive impairment and Alzheimer's disease (Nesteruk et al, 2016;Nishioka et al, 2015), demyelinating diseases, such as multiple sclerosis (de Kouchkovsky et al, 2016), and neuropsychiatric diseases, such as depression and schizophrenia (Jiang et al, 2017;Singh et al, 2016). Most of these studies have focused on WM or deep GM such as the hippocampus, because these brain regions have high directionality in water diffusion (Manna et al, 2015;Ziyan and Westin, 2008), whereas water diffusion in the cerebral cortex has an isotropic direction at the level of conventional DTI resolution (Elman et al, 2017).…”
Background:Diffusion tensor imaging (DTI), which is a technique for measuring the degree and direction of movement of water molecules in tissue, has been widely used to noninvasively assess white matter (WM) or gray matter (GM) microstructures in vivo. Mean diffusivity (MD), which is the average diffusion across all directions, has been considered as a marker of WM tract degeneration or extracellular space enlargement in GM. Recent lines of evidence suggest that cortical MD can better identify early-stage Alzheimer’s disease than structural morphometric parameters in magnetic resonance imaging. However, knowledge of the relationships between cortical MD and other biological factors in the same cortical region, e.g. metabolites, is still limited.Methods:Thirty-three healthy elderly individuals [aged 50–77 years (mean, 63.8±7.4 years); 11 males and 22 females] were enrolled. We estimated the associations between cortical MD and neurotransmitter levels. Specifically, we measured levels of γ-aminobutyric acid (GABA) and glutamate + glutamine (Glx), which are inhibitory and excitatory neurotransmitters, respectively, in medial prefrontal cortex (mPFC) and posterior cingulate cortex (PCC) using MEGA-PRESS magnetic resonance spectroscopy, and we measured regional cortical MD using DTI.Results:Cortical MD was significantly negatively associated with Glx levels in both mPFC and PCC. No significant association was observed between cortical MD and GABA levels in either GM region.Conclusion:Our findings suggest that degeneration of microstructural organization in GM, as determined on the basis of cortical MD measured by DTI, is accompanied by the decline of Glx metabolism within the same GM region.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.